Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)

PURPOSE: Patients with persistent/recurrent cervical cancer following platinum-based chemotherapy have limited therapeutic options. The Gynecologic-Oncology-Group conducted a phase II trial to assess efficacy and tolerability of nivolumab, an immune checkpoint inhibitor, in persistent/recurrent cerv...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Gynecol Oncol
Autores principales: Santin, Alessandro D., Deng, Wei, Frumovitz, Michael, Buza, Natalia, Bellone, Stefania, Huh, Warner, Khleif, Samir, Lankes, Heather A., Ratner, Elena S., O’Cearbhaill, Roisin E., Jazaeri, Amir A., Birrer, Michael
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7127981/
https://ncbi.nlm.nih.gov/pubmed/31924334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2019.12.034
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares